A central problem for the development of HIV-1 vaccines has been to identify immunogen determinant capable of raising high titer, long lasting, neutralizing antibody against the envelope glycoproteins (Envs) of primary isolates. The HIV-1 Env has proven to be a weak immunogen raising low titer antibodies that are slow to undergo affinity maturation. In this proposal, DNA and protein immunogens will be used to test the C3d component of complement as a molecular adjuvant for Env. In normal immune responses the attachment of C3d to an antigen enhances both the initiation and the maturation of antigen-specific antibody. To test a potential adjuvant role of C3d for Env, DNA constructs will be produced encoding Env fused to C3d. These constructs will be used for DNA immunizations and to produce protein for protein immunizations. The study will be executed according to three specific aims. (l) Vaccinate with plasmids encoding secreted monomeric (gpl20) and oligomeric (gpl40) forms of a primary Env (89.6) and using these same forms of Env fused at the carboxyl terminus to one, two or three tandem copies of C3d will be constructed. (2) Plasmid constructs will be expressed to (a) determine the levels of expression and secretion of the various Envs, (b) to test the various Envs for the maintenance of native/functional conformations, and (c) to purify selected Envs for protein immunizations. (3) Env constructs will be compared for immunogenicity in mice, using DNA immunizations. For the more favorable constructs, DNA immunizations plus protein boosts, and protein immunizations will be conducted. Raised antibody will be titered for the level of Env-specific IgG and for neutralizing activity for a panel of primary as well as T-cell line adapted HIV-1 isolates. Our goal is to identify the most favorable Env-C3d fusion for raising high titer neutralizing antibody for HIV-l. The hypothesis throughout the study is that the C3d fusions will increase the immunogenicity of Env both by increasing the efficiency of the initiation of anti-Env Ab responses and by increasing the ability of anti-Env Ab to undergo affinity maturation.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Exploratory/Developmental Grants (R21)
Project #
1R21AI044325-01
Application #
2752114
Study Section
Special Emphasis Panel (ZAI1-PRJ-A (S1))
Project Start
1998-09-30
Project End
2000-09-29
Budget Start
1998-09-30
Budget End
1999-09-29
Support Year
1
Fiscal Year
1998
Total Cost
Indirect Cost
Name
Emory University
Department
Microbiology/Immun/Virology
Type
Schools of Medicine
DUNS #
042250712
City
Atlanta
State
GA
Country
United States
Zip Code
30322
Bower, Joseph F; Yang, Xinzhen; Sodroski, Joseph et al. (2004) Elicitation of neutralizing antibodies with DNA vaccines expressing soluble stabilized human immunodeficiency virus type 1 envelope glycoprotein trimers conjugated to C3d. J Virol 78:4710-9
Bower, Joseph F; Green, Thomas D; Ross, Ted M (2004) DNA vaccines expressing soluble CD4-envelope proteins fused to C3d elicit cross-reactive neutralizing antibodies to HIV-1. Virology 328:292-300
Young, Kelly R; Teal, Benjamin E; Brooks, Yvonne et al. (2004) Unique V3 loop sequence derived from the R2 strain of HIV-type 1 elicits broad neutralizing antibodies. AIDS Res Hum Retroviruses 20:1259-68
Green, Thomas D; Montefiori, David C; Ross, Ted M (2003) Enhancement of antibodies to the human immunodeficiency virus type 1 envelope by using the molecular adjuvant C3d. J Virol 77:2046-55
Ross, T M; Xu, Y; Green, T D et al. (2001) Enhanced avidity maturation of antibody to human immunodeficiency virus envelope: DNA vaccination with gp120-C3d fusion proteins. AIDS Res Hum Retroviruses 17:829-35
Green, T D; Newton, B R; Rota, P A et al. (2001) C3d enhancement of neutralizing antibodies to measles hemagglutinin. Vaccine 20:242-8
Ross, T M (2001) Using death to one's advantage: HIV modulation of apoptosis. Leukemia 15:332-41
Ross, T M; Xu, Y; Bright, R A et al. (2000) C3d enhancement of antibodies to hemagglutinin accelerates protection against influenza virus challenge. Nat Immunol 1:127-31